A new perspective on optimal care for patients with COPD

Primary Care Respiratory Journal

Volumn 20, Issue 2, 2011, Pages 205-209

  Postma, Dirkje ^a   Anzueto, Antonio ^b   Calverley, Peter ^c   Jenkins, Christine ^d   Make, Barry J ^e   Sciurba, Frank C ^f   Similowski, Thomas ^g   van der Molen, Thys ^a   Eriksson, Göran ^h  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^c UNIVERSITY HOSPITAL AINTREE   (United Kingdom)

^d UNIVERSITY OF SYDNEY   (Australia)

^e UNIVERSITY OF COLORADO   (United States)

^f UNIVERSITY OF PITTSBURGH   (United States)

^g PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^h ASTRAZENECA R AND D   (Sweden)

Author keywords

Care; COPD; Future; Management; Risk reduction; Today

Indexed keywords

ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL RESEARCH; DISEASE CONTROL; DISEASE EXACERBATION; GENERAL PRACTICE; HUMAN; MEDICAL DECISION MAKING; PATIENT ASSESSMENT; PATIENT CARE; PRACTICE GUIDELINE; RISK ASSESSMENT; RISK REDUCTION;

DISEASE MANAGEMENT; HUMANS; PRACTICE GUIDELINES AS TOPIC; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

EID: 79957898604     PISSN: 14714418     EISSN: 14751534     Source Type: Journal    
DOI: 10.4104/pcrj.2011.00041     Document Type: Article

References (20)

1. Rennard SI, Vestbo J. The many small COPDs: COPD should be an orphan disease. Chest 2008;134(3):623-627. http://dx.doi.org/10.1378/chest.07-3059
2. Price D, Crockett A, Arne M, et al. Spirometry in primary care case-identification, diagnosis and management of COPD. Prim Care Respir J 2009;18(3):216-223. http://dx.doi.org/10.4104/pcrj.2009.00055
3. Anthonisen NR, Skeans MA, Wise RA, Manfreda J, Kanner RE, Connett JE. The effects of a smoking cessation intervention on 14.5-year mortality: a randomized clinical trial. Ann Intern Med 2005;142(4):233-239.
4. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Updated 2009. 2009. Available at: http://goldcopd.org/Guidelineitem.asp?l1=2&l2=1&intId=2003 (accessed 1.3.2010).
5. Wedzicha JA, Calverley PM, Seemungal TA, Hagan G, Ansari Z, Stockley RA. The prevention of COPD exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. Am J Respir Crit Care Med 2008;177(1):19-26. http://dx.doi.org/10.1164/rccm.200707-973OC
6. Puhan MA, Bachmann LM, Kleijnen J, Ter Riet G, Kessels AG. Inhaled drugs to reduce exacerbations in patients with chronic obstructive pulmonary disease: a network meta-analysis. BMC Med 2009;7:2. http://dx.doi.org/10.1186/1741-7015-7-2
7. Celli BR, Thomas NE, Anderson JA, et al. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. Am J Respir Crit Care Med 2008;178(4):332-338. http://dx.doi.org/10.1164/rccm.200712-1869OC
8. Lapperre TS, Snoeck-Stroband JB, Gosman MM, et al. Effect of fluticasone with and without salmeterol on pulmonary outcomes in chronic obstructive pulmonary disease: a randomized trial. Ann Intern Med 2009;151(8):517-527.
9. Calverley PMA, Anderson JA, Celli B, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007;356(8):775-789. http://dx.doi.org/10.1056/NEJMoa063070
10. Weiner SD, Rabbani LE. Secondary prevention strategies for coronary heart disease. J Thromb Thrombolysis 2010;29(1):8-24. http://dx.doi.org/10.1007/s11239-009-0381-8
11. Kocks JWH, Asijee GM, Tsiligianni IG, Kerstjens HAM, van der Molen T. Functional status measurement in COPD: a review of available methods and their feasibility in primary care. Prim Care Respir J 2011 (in press) http://dx.doi.org/10.4104/pcrj.2011.00031
12. Casanova C, Cote C, de Torres JP, et al. Inspiratory-to-total lung capacity ratio predicts mortality in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2005;171(6):591-597. http://dx.doi.org/10.1164/rccm.200407-867OC
13. Postma DS, De Vries K, Koeter GH, Sluiter HJ. Independent influence of reversibility of air-flow obstruction and nonspecific hyperreactivity on the long-term course of lung function in chronic air-flow obstruction. Am Rev Respir Dis 1986;134(2):276-280.
14. de Torres JP, Pinto-Plata V, Casanova C, et al. C-reactive protein levels and survival in patients with moderate to very severe COPD. Chest 2008;133(6):1336-1343. http://dx.doi.org/10.1378/chest.07-2433
15. Spencer S, Calverley PM, Sherwood BP, Jones PW. Health status deterioration in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001;163(1):122-128.
16. Niewoehner DE. The impact of severe exacerbations on quality of life and the clinical course of chronic obstructive pulmonary disease. Am J Med 2006;119(10 Suppl 1):38-45. http://dx.doi.org/10.1016/j.amjmed.2006.08.006
17. Wedzicha JA, Seemungal TA. COPD exacerbations: defining their cause and prevention. Lancet 2007;370(9589):786-796.
18. Anzueto A, Sethi S, Martinez FJ. Exacerbations of chronic obstructive pulmonary disease. Proc Am Thorac Soc 2007;4(7):554-564. http://dx.doi.org/10.1513/pats.200701-003FM
19. Hurst JR, Vestbo J, Anzueto A, et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med 2010;363(12):1128-1138. http://dx.doi.org/10.1056/NEJMoa0909883
20. Marin JM, Carrizo SJ, Casanova C, et al. Prediction of risk of COPD exacerbations by the BODE index. Respir Med 2009;103(3):373-378. http://dx.doi.org/10.1016/j.rmed.2008.10.004